Zurcher Kantonalbank Zurich Cantonalbank Has $122,000 Stock Position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Zurcher Kantonalbank Zurich Cantonalbank grew its position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 62.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 22,571 shares of the company’s stock after purchasing an additional 8,676 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Eyepoint Pharmaceuticals were worth $122,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Raymond James Financial Inc. acquired a new position in Eyepoint Pharmaceuticals during the fourth quarter worth $76,000. Vanguard Group Inc. increased its holdings in Eyepoint Pharmaceuticals by 24.8% during the fourth quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company’s stock worth $28,334,000 after buying an additional 755,045 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Eyepoint Pharmaceuticals by 6.4% during the fourth quarter. JPMorgan Chase & Co. now owns 395,444 shares of the company’s stock worth $2,946,000 after purchasing an additional 23,686 shares during the period. Wellington Management Group LLP boosted its position in Eyepoint Pharmaceuticals by 3.2% during the fourth quarter. Wellington Management Group LLP now owns 177,316 shares of the company’s stock worth $1,321,000 after purchasing an additional 5,552 shares during the period. Finally, Geode Capital Management LLC boosted its position in Eyepoint Pharmaceuticals by 28.3% during the fourth quarter. Geode Capital Management LLC now owns 1,538,902 shares of the company’s stock worth $11,467,000 after purchasing an additional 339,846 shares during the period. 99.41% of the stock is owned by institutional investors.

Eyepoint Pharmaceuticals Trading Up 1.6%

Eyepoint Pharmaceuticals stock opened at $10.23 on Monday. The firm has a 50 day moving average of $9.65 and a 200 day moving average of $7.44. The firm has a market capitalization of $703.93 million, a price-to-earnings ratio of -3.82 and a beta of 1.73. Eyepoint Pharmaceuticals, Inc. has a 12-month low of $3.91 and a 12-month high of $13.98.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.18). The firm had revenue of $5.33 million during the quarter, compared to analysts’ expectations of $6.82 million. Eyepoint Pharmaceuticals had a negative return on equity of 61.64% and a negative net margin of 337.93%. On average, analysts predict that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on EYPT. Chardan Capital reiterated a “buy” rating and set a $27.00 target price on shares of Eyepoint Pharmaceuticals in a research report on Thursday. HC Wainwright lifted their target price on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday, August 6th. Mizuho reduced their price objective on shares of Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an “outperform” rating on the stock in a research report on Friday, May 16th. Finally, Royal Bank Of Canada assumed coverage on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, June 17th. They set an “outperform” rating and a $28.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $25.78.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.